Articles tagged with Phenylketonuria
SYNB1618 demonstrates dose-responsive, non-saturated increases in gastrointestinal Phe consumption, suggesting therapeutic potential for Phenylketonuria (PKU). A mechanistic model predicts SYNB1618's function in PKU patients and informs clinical development.
Researchers develop stable capsule shell for L-phenylalanine ammonium-liasis (PAL) enzyme, improving its effectiveness and stability in the body. The treatment has potential applications beyond phenylketonuria, including other amino acid metabolism disorders.
Researchers at IKBFU developed a stable capsule composition for the L-phenylalanine-ammonium lyase enzyme to treat phenylketonuria. The study found that storage temperatures above 25°C significantly decrease enzyme activity, but the optimal temperature remains unknown.
Researchers identified four small molecules that stabilize both normal and mutated PAH proteins, increasing their activity and amount in human cells. These findings suggest chaperones might provide a new approach to treating individuals with phenylketonuria.
Researchers at University of Wisconsin-Madison discover a unique protein in whey that supports growth and reduces phenylalanine levels in mice with PKU, opening possibilities for dietary liberalization.